NDAORALCAPSULEPriority Review
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
Priority Review
VIVJOA (oteseconazole) by Mycovia Pharmaceuticals is breast cancer resistance protein inhibitors [moa]. Approved for vulvovaginal candidiasis. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVJOA (oteseconazole) is an oral azole antifungal that inhibits the Breast Cancer Resistance Protein to treat vulvovaginal candidiasis. It represents a novel mechanism within the azole class, offering systemic oral dosing as an alternative to topical formulations. The drug addresses a common gynecological infection affecting millions of women annually.
$0.222MPart D
Peak9.9 years to LOEEarly-stage uptake with minimal Part D spending signals a niche market position; brand team size likely remains lean with focus on awareness and adoption strategies.
Mechanism of Action
Breast Cancer Resistance Protein Inhibitors
Pharmacologic Class:
Azole Antifungal
Indications (1)
Clinical Trials (3)
Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Started Mar 2019
219 enrolled
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Started Aug 2018
425 enrolled
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Started Aug 2018
438 enrolled
Recurrent Vulvovaginal Candidiasis
Worked on VIVJOA at Mycovia Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.